Gapicomine
 | |
| Clinical data | |
|---|---|
| Routes of administration | oral (tablet) |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H13N3 |
| Molar mass | 199.25 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Gapicomine (INN) is a coronary vasodilator. It has been withdrawn from the market in the countries it was used in.[1]
Also, gapicomine is a major component in the drug Bicordin.[2]
History
Gapicomine was discovered in 1970 by Polish chemist Stanisław Biniecki. It was first published about in an article of The Polish Journal of Medicine and Pharmacy describing the derivative drug Bicordin in 1974.[3]
References
- ^ "Gapicomine Monograph, The Index Nominum". Retrieved 2008-03-31.
- ^ "Bicordin, PubChem". Retrieved 2008-03-31.
- ^ Samochowiec L, Wójcicki J, Gregorczyk K, Szmatloch E (1974). "Bicordin--a new drug in the treatment of coronary heart disease". Mater Med Pol. 6 (4): 298–300. PMID 4453155.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |